摘要
目的 :探讨降纤酶对不稳定型心绞痛(UAP)的临床疗效。方法 :在抗心绞痛常规疗法基础上 ,治疗组30例用降纤酶10u静脉滴注 ,每天1次 ,共5d ;对照组30例用脉络宁30ml静脉滴注 ,每天1次 ,共10d。6d后考核疗效及有关实验室指标。结果 :治疗组、对照组的临床总有效率各为96 66 %和70 %(P<0 01) ,治疗期间治疗组的硝酸甘油用量、镇痛药使用次数较对照组少(P<0 01和0 05)。治疗组治疗前后的血小板计数(PLT) ,凝血酶原时间(PT) ,激活的部分凝血活酶时间(APTT)均无显著变化 ,而纤维蛋白原(FIBEN)明显降低(P<0 01) ;对照组治疗前后4项指标则无显著性差异(P>0 05)。结论 :降纤酶治疗UAP疗效好 ,能降低FIBEN水平 ,使用方便。
Objective: To investigate the clinical effects of treating unstable angina pectoris (UAP) with defibrase. Methods: Besides routine antiangina therapy, 30 cases of patients in the tested group were given defibrase 10 u with intravenous dripping, once daily for 5 days. 30 cases in the control group were given 30 ml of MaiLuoning instead of defibrase, intravenously dripped once daily for ten days. 6 days after the treatments, we took the clinical and laboratory results. Results: The clinical effective rates of the tested group and control group were 96.66% and 70%, respectively (P<0.01). During therapeutic period, the quantity and using times of nitroglycerin in the tested group were lower than those in the control group (P<0.01 and P<0.05, respectively). There were no significant changes in platelet count (PLT), plasma prothrombin time (PT) and activated partial thrombplastin time (APTT) while the fibrinogen (FIBEN) level reduced (P<0.01) in the tested group after treatment. Compared with before treatment, above indexes had no statistical differences in the control group. Conclusion: Defibrase is of ideal clinical effects for treating UAP. It is also safety and convenient to be used.
出处
《大理医学院学报》
2000年第2期24-25,共2页
Journal of Dali Medical College
关键词
降纤酶
不稳定心绞痛
治疗
Defibrase
Unstable angina pectoris
Treatment
